S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in

DexCom Stock Forecast, Price & News

-11.78 (-3.26 %)
(As of 01/27/2021 12:00 AM ET)
Today's Range
Now: $349.64
50-Day Range
MA: $361.63
52-Week Range
Now: $349.64
Volume1.03 million shs
Average Volume994,213 shs
Market Capitalization$33.58 billion
P/E Ratio144.48
Dividend YieldN/A
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; a collaboration with Companion Medical, Inc.; and a development and commercialization agreement with Tandem Diabetes Care, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
DexCom logo


Overall MarketRank

1.86 out of 5 stars

Medical Sector

114th out of 1,926 stocks

Surgical & Medical Instruments Industry

14th out of 169 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Current SymbolNASDAQ:DXCM
Year FoundedN/A



Sales & Book Value

Annual Sales$1.48 billion
Cash Flow$2.31 per share
Book Value$9.64 per share


Net Income$101.10 million


Market Cap$33.58 billion
Next Earnings Date2/11/2021 (Confirmed)
-11.78 (-3.26 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DexCom (NASDAQ:DXCM) Frequently Asked Questions

How has DexCom's stock been impacted by Coronavirus?

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 38.5% and is now trading at $349.64.
View which stocks have been most impacted by COVID-19

Is DexCom a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than DexCom?

Wall Street analysts have given DexCom a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DexCom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for DexCom

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings data on Tuesday, October, 27th. The medical device company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.64 by $0.30. The medical device company earned $500.90 million during the quarter, compared to analysts' expectations of $477.22 million. DexCom had a net margin of 12.69% and a trailing twelve-month return on equity of 27.29%.
View DexCom's earnings history

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $567 million, compared to the consensus revenue estimate of $550.73 million.

What price target have analysts set for DXCM?

18 brokers have issued 1-year price targets for DexCom's stock. Their forecasts range from $240.00 to $500.00. On average, they anticipate DexCom's stock price to reach $417.12 in the next year. This suggests a possible upside of 19.3% from the stock's current price.
View analysts' price targets for DexCom
or view Wall Street analyst' top-rated stocks.

Are investors shorting DexCom?

DexCom saw a increase in short interest in December. As of December 31st, there was short interest totaling 3,490,000 shares, an increase of 19.9% from the December 15th total of 2,910,000 shares. Based on an average trading volume of 1,120,000 shares, the days-to-cover ratio is currently 3.1 days.
View DexCom's Short Interest

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 63, Pay $2.09M)
  • Mr. Quentin S. Blackford, CFO & COO (Age 42, Pay $1.17M)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 49, Pay $873.62k)
  • Mr. Andrew K. Balo, Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. (Age 73, Pay $875.97k)
  • Mr. Jereme Sylvain, Sr. VP of Fin., Chief Accounting Officer & Corp. Controller (Age 41)
  • Mr. Jacob Steven Leach, Exec. VP & CTO (Age 43)
  • Mr. Sean Christensen, Sr. Investor Relations Mang.
  • Mr. Patrick Michael Murphy, Exec. VP & Chief Legal Officer (Age 42)
  • Chad Patterson, Sr. VP of Global Marketing
  • Ms. Sadie M. Stern, Exec. VP & Chief HR Officer (Age 46)

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (0.24%), Chicago Capital LLC (0.16%), New York State Teachers Retirement System (0.13%), Strs Ohio (0.12%), Peregrine Capital Management LLC (0.11%) and Scout Investments Inc. (0.05%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom

Which major investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC, Pacer Advisors Inc., Congress Asset Management Co. MA, Kovack Advisors Inc., Candriam Luxembourg S.C.A., State of Alaska Department of Revenue, First Bank & Trust, and Joel Isaacson & Co. LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom
or view top insider-selling stocks.

Which major investors are buying DexCom stock?

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, Scout Investments Inc., Peregrine Capital Management LLC, Frontier Capital Management Co. LLC, Chicago Capital LLC, Kestra Private Wealth Services LLC, Louisiana State Employees Retirement System, and Exchange Traded Concepts LLC.
View insider buying and selling activity for DexCom
or or view top insider-buying stocks.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $349.64.

How big of a company is DexCom?

DexCom has a market capitalization of $33.58 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.